Targeting TL1A in IBD to Treat Both Inflammation and Fibrosis – A Wheel of Knowledge Challenge!
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
The EoE Playbook: Clues, Criteria, and Clinical Confirmation
This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
The EoE Playbook: Evidence-Driven EoE Management
This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
The EoE Playbook: Navigating Access to Advanced Therapy
This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
The EoE Playbook
This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
TL1A Inhibition for IBD: Emerging Therapies at the Intersection of Inflammation and Fibrosis
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Pediatric EoE: From Diagnosis to Biologic Advancements
This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
IBD Advancements: The Promise of TL1A-Targeted Therapies
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
IBD Summit: From Rapid-Fire Insights to Real-World Cases
This activity is supported by educational grants from AbbVie Inc.; Genentech, a member of the Roche Group; Johnson & Johnson; Merck & Co., Inc.; and Takeda Pharmaceuticals U.S.A., Inc.